{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=21",
    "query": {
      "intervention": "Formulation #2",
      "page": 21
    },
    "page_size": 10
  },
  "pagination": {
    "page": 21,
    "page_size": 10,
    "total_count": 1742,
    "total_pages": 175,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=22&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=20&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-01T10:42:01.358Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03566199",
      "title": "MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Intrinsic Pontine Glioma"
      ],
      "interventions": [
        {
          "name": "Panobinostat Nanoparticle Formulation MTX110",
          "type": "DRUG"
        },
        {
          "name": "Convection-Enhanced Delivery (CED)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sabine Mueller, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 7,
      "start_date": "2018-05-22",
      "completion_date": "2021-03-31",
      "has_results": true,
      "last_update_posted_date": "2022-02-25",
      "last_synced_at": "2026-11-01T10:42:01.358Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03566199"
    },
    {
      "nct_id": "NCT01010698",
      "title": "Class 3 Biowaivers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "cimetidine (or acyclovir)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 48,
      "start_date": "2009-06",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2020-11-06",
      "last_synced_at": "2026-11-01T10:42:01.358Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01010698"
    },
    {
      "nct_id": "NCT02357966",
      "title": "Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Staphylococcus Aureus Bacteremia"
      ],
      "interventions": [
        {
          "name": "514G3 (2 mg/kg) plus standard IV antibiotic treatment",
          "type": "BIOLOGICAL"
        },
        {
          "name": "514G3 (10 mg/kg) plus standard IV antibiotic treatment",
          "type": "BIOLOGICAL"
        },
        {
          "name": "514G3 (40 mg/kg) plus standard IV antibiotic treatment",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo plus standard IV antibiotic treatment",
          "type": "OTHER"
        },
        {
          "name": "514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo plus standard IV antibiotic treatment: Phase II",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "XBiotech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2015-05",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2026-02-09",
      "last_synced_at": "2026-11-01T10:42:01.358Z",
      "location_count": 2,
      "location_summary": "Columbus, Georgia • Charlotte, North Carolina",
      "locations": [
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02357966"
    },
    {
      "nct_id": "NCT02479139",
      "title": "Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hyperhidrosis"
      ],
      "interventions": [
        {
          "name": "Vehicle",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ANT-1207",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 145,
      "start_date": "2015-06-03",
      "completion_date": "2016-02-29",
      "has_results": true,
      "last_update_posted_date": "2017-09-20",
      "last_synced_at": "2026-11-01T10:42:01.358Z",
      "location_count": 19,
      "location_summary": "Hialeah, Florida • Miami, Florida • Pinellas Park, Florida + 16 more",
      "locations": [
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Pinellas Park",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Carmel",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02479139"
    },
    {
      "nct_id": "NCT04548219",
      "title": "A Study to Compare Two Different Formulations of Mirikizumab in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Mirikizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 60,
      "start_date": "2020-09-11",
      "completion_date": "2021-01-11",
      "has_results": true,
      "last_update_posted_date": "2024-01-25",
      "last_synced_at": "2026-11-01T10:42:01.358Z",
      "location_count": 1,
      "location_summary": "Springfield, Missouri",
      "locations": [
        {
          "city": "Springfield",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04548219"
    },
    {
      "nct_id": "NCT00853216",
      "title": "Fasting Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Oxycodone hydrochloride tablet 30 mg",
          "type": "DRUG"
        },
        {
          "name": "Roxicodone™ tablet 30 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mallinckrodt",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2003-01",
      "completion_date": "2003-02",
      "has_results": false,
      "last_update_posted_date": "2016-10-19",
      "last_synced_at": "2026-11-01T10:42:01.358Z",
      "location_count": 1,
      "location_summary": "Saint Charles, Missouri",
      "locations": [
        {
          "city": "Saint Charles",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00853216"
    },
    {
      "nct_id": "NCT02156375",
      "title": "A Pharmacokinetic Study of Single-Dose Intravenous Ustekinumab Delivered in 2 Different Liquid in Vial Formulations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Ustekinumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 140,
      "start_date": "2014-05",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2016-03-22",
      "last_synced_at": "2026-11-01T10:42:01.358Z",
      "location_count": 3,
      "location_summary": "Tempe, Arizona • Lincoln, Nebraska • Neptune City, New Jersey",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        },
        {
          "city": "Neptune City",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02156375"
    },
    {
      "nct_id": "NCT00802464",
      "title": "Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Herpes Zoster"
      ],
      "interventions": [
        {
          "name": "Herpes zoster vaccine GSK1437173A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 410,
      "start_date": "2009-01-12",
      "completion_date": "2010-07-02",
      "has_results": true,
      "last_update_posted_date": "2019-06-26",
      "last_synced_at": "2026-11-01T10:42:01.358Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Pembroke Pines, Florida • Las Vegas, Nevada + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Edison",
          "state": "New Jersey"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00802464"
    },
    {
      "nct_id": "NCT03847987",
      "title": "A 2 Part Study to Assess the Relative Bioavailability of Tablet Formulation Compared to Capsule Formulation and the Effect of Food and Taste Assessment on the Tablet Formulation in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "RO7017773 Phase I Capsule",
          "type": "DRUG"
        },
        {
          "name": "RO7017773 Phase II Tablet Unflavored",
          "type": "DRUG"
        },
        {
          "name": "RO7017773 Phase II Tablet Sweetened/Flavored",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2019-03-12",
      "completion_date": "2019-04-22",
      "has_results": true,
      "last_update_posted_date": "2020-05-28",
      "last_synced_at": "2026-11-01T10:42:01.358Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03847987"
    },
    {
      "nct_id": "NCT01388829",
      "title": "Study To Assess The Pharmacokinetics Of 2 Different Formulations Of PF-04991532",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Treatment A",
          "type": "DRUG"
        },
        {
          "name": "Treatment B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 10,
      "start_date": "2011-07",
      "completion_date": "2011-08",
      "has_results": false,
      "last_update_posted_date": "2011-08-10",
      "last_synced_at": "2026-11-01T10:42:01.358Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01388829"
    }
  ]
}